Clinical Trial Detail

NCT ID NCT02203903
Title Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Catherine Bollard
Indications

mantle cell lymphoma

leukemia

chronic myeloid leukemia

anaplastic large cell lymphoma

Hodgkin's lymphoma

gray zone lymphoma

myelodysplastic syndrome

lymphoma

acute lymphoblastic leukemia

acute myeloid leukemia

Therapies

MultiTAA-specific T cells

Age Groups: child adult senior

No variant requirements are available.